Protara Therapeutics' Q2 net loss widens

Protara Therapeutics

11/08/2025 13:12

Overview

Protara Therapeutics' Q2 net loss widens to $15.0 mln from $9.5 mln, missing analysts' expectations

Adjusted EPS of -$0.35 beat analysts' estimates, per LSEG data

Cash reserves expected to fund operations into mid-2027

Outlook

Protara to present ADVANCED-2 trial interim results in 1Q 2026

Company on track to dose first patient in THRIVE-3 trial in 3Q 2025

Interim update from STARBORN-1 trial expected in 4Q 2025

Cash reserves to support operations into mid-2027

Result Drivers

CLINICAL TRIAL PROGRESS - Increased R&D expenses driven by ongoing trials for TARA-002 and IV Choline Chloride

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
Beat
-$0.35
-$0.41 (6 Analysts)
Q2 Net Income
Miss
-$14.96 mln
-$13 mln (5 Analysts)
Q2 Income from Operations
Miss
-$16.59 mln
-$14.10 mln (5 Analysts)
Q2 Operating Expenses
$16.59 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Protara Therapeutics Inc is $22.50, about 86.1% above its August 8 closing price of $3.13

Press Release: ID:nGNX8Pv0Yj

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)